RNA (Atrium Therapeutics) Accounts Payable: $0.81 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.35
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Accounts Payable?

Atrium Therapeutics RNA +1.52% 12 Accounts Payable is $0.81 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $0.81 Mil.

Atrium Therapeutics's quarterly Accounts Payable increased from Sep. 2025 ($0.45 Mil) to Dec. 2025 ($4.40 Mil) but then declined from Dec. 2025 ($4.40 Mil) to Mar. 2026 ($0.81 Mil).

Atrium Therapeutics's annual Accounts Payable increased from Dec. 2023 ($0.50 Mil) to Dec. 2024 ($0.53 Mil) and increased from Dec. 2024 ($0.53 Mil) to Dec. 2025 ($4.40 Mil).

Atrium Therapeutics Accounts Payable Related Terms

Atrium Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Accounts Payable Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Accounts Payable
0.50 0.53 4.40

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial 0.53 0.00 0.45 4.40 0.81
RNA
12GF Score
Atrium Therapeutics Inc RNA
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.81 Mil mean?
Atrium Therapeutics (RNA) has a Accounts Payable of $0.81 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Accounts Payable too high?
Atrium Therapeutics' current Accounts Payable is $0.81 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Accounts Payable compare to CNTN and QTTB?
Atrium Therapeutics' Accounts Payable of $0.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Accounts Payable is $0.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Accounts Payable of $0.81 Mil. The current Accounts Payable is $0.81 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Accounts Payable is $0.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.35
Price